Related Experiment Video

Updated: Jan 9, 2026

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.9K

PolyBodies for the Treatment of Respiratory Syncytial Virus Infection

Yenisetti Rajendra Prasad1, Sandeep1, Prakash Y Khandave1

  • 1Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar, Mohali 160062 Punjab, India.

Drug Discovery Today
|December 6, 2025
PubMed

Insights

New nanobody treatments show promise for respiratory syncytial virus (RSV) infections. These advanced therapies, including PolyBodies, offer potential for broader, longer-lasting protection against RSV, addressing limitations of current options.

Area of Science:

  • Virology
  • Immunology
  • Nanotechnology

Background:

  • Respiratory syncytial virus (RSV) causes significant lower respiratory tract infections and hospitalizations, particularly in vulnerable groups.
  • Current RSV prophylactics targeting the F protein offer some protection but lack broad impact and long-lasting efficacy.
  • There is a critical need for more effective and durable treatments against RSV.

Purpose of the Study:

  • To review existing therapies for respiratory syncytial virus (RSV).
  • To explore the potential of nanobodies as a novel treatment strategy for RSV infections.
  • To highlight the significance of PolyBodies (polyspecific and polyvalent antibodies) in managing RSV.

Main Methods:

  • Literature review of current RSV prophylactics and emerging nanobody research.
  • Analysis of the mechanisms and potential applications of nanobodies against RSV.
  • Discussion of the advantages of polyspecific and polyvalent antibodies (PsAbs and PvAbs) for RSV treatment.

Main Results:

  • Existing RSV treatments have limitations in efficacy and duration.
  • Nanobodies present a promising alternative due to their unique properties.
  • PolyBodies offer potential for enhanced and sustained protection against RSV.

Conclusions:

  • Nanobodies, especially PolyBodies, represent a significant advancement in the development of new RSV therapies.
  • Further research into nanobody-based treatments is crucial for combating RSV epidemics.
  • These novel approaches could provide improved protection for at-risk populations.

Keywords:
PolyBodiesantibody engineeringantiviralmonoclonal antibodiesrespiratory syncytial virussingle-domain antibodies

More Related Videos

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.2K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.4K

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
604
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
731
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
1.2K
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
1.0K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
425